Stefano Ciardullo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8340669/publications.pdf

Version: 2024-02-01

45 papers

915 citations

567281 15 h-index 552781 26 g-index

46 all docs 46 docs citations

46 times ranked 866 citing authors

#	Article	IF	CITATIONS
1	Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver International, 2021, 41, 1290-1293.	3.9	134
2	High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes. Diabetes Care, 2021, 44, 519-525.	8.6	102
3	Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Research and Care, 2020, 8, e000904.	2.8	71
4	Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017–2018 National Health and Nutrition Examination Survey. Clinical Gastroenterology and Hepatology, 2021, 19, 384-390.e1.	4.4	60
5	Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism: Clinical and Experimental, 2021, 121, 154752.	3.4	47
6	Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2022, 34, 365-371.	1.6	42
7	Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy. Journal of Endocrinological Investigation, 2021, 44, 843-850.	3.3	41
8	Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. Hypertension, 2020, 76, 562-568.	2.7	39
9	Sex-related association of nonalcoholic fatty liver disease and liver fibrosis with body fat distribution in the general US population. American Journal of Clinical Nutrition, 2022, 115, 1528-1534.	4.7	34
10	NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2856-e2865.	3.6	26
11	Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. Biomolecules, 2022, 12, 105.	4.0	23
12	Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population. Digestive and Liver Disease, 2021, 53, 866-872.	0.9	22
13	Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005–2016. Diabetes Research and Clinical Practice, 2020, 167, 108358.	2.8	19
14	Screening of SLC2A1 in a large cohort of patients suspected for Glut1 deficiency syndrome: identification of novel variants and associated phenotypes. Journal of Neurology, 2019, 266, 1439-1448.	3.6	18
15	Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2022, 190, 109981.	2.8	18
16	Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population. Journal of Hypertension, 2021, 39, 1621-1627.	0.5	17
17	Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease. American Journal of Nephrology, 2021, 52, 666-672.	3.1	16
18	Soluble α-Klotho levels, glycemic control and renal function in US adults with type 2 diabetes. Acta Diabetologica, 2022, 59, 803-809.	2.5	14

#	Article	IF	CITATIONS
19	Is Switching from Oral Antidiabetic Therapy to Insulin Associated with an Increased Fracture Risk?. Clinical Orthopaedics and Related Research, 2020, 478, 992-1003.	1.5	13
20	Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. Journal of Endocrinological Investigation, 2020, 43, 1019-1026.	3.3	13
21	Resting Energy Expenditure in Obese Women with Primary Hypothyroidism and Appropriate Levothyroxine Replacement Therapy. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1741-e1748.	3.6	12
22	Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting. Diabetes Research and Clinical Practice, 2021, 180, 109035.	2.8	12
23	Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2671-e2679.	3.6	12
24	Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents. Hepatology Communications, 2022, 6, 2070-2078.	4.3	12
25	Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population. Frontiers in Endocrinology, 2021, 12, 711484.	3.5	11
26	Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. Women. Diabetes Research and Clinical Practice, 2021, 177, 108879.	2.8	8
27	Risk stratification tools for heart failure in the diabetes clinic. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1070-1079.	2.6	7
28	Baseline TSH levels and short-term weight loss after different procedures of bariatric surgery. International Journal of Obesity, 2021, 45, 326-330.	3.4	7
29	Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines. Pharmacological Research, 2021, 166, 105530.	7.1	7
30	Seasonal variation in estimated cardiovascular risk in patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1494-1500.	2.6	7
31	Twenty-year trends in heart failure among U.S. adults, 1999–2018: The growing impact of obesity and diabetes. International Journal of Cardiology, 2022, 362, 104-109.	1.7	7
32	Visit-to-visit blood pressure variability in patients with type 2 diabetes with and without previous history of cardiovascular disease. Journal of Hypertension, 2020, 38, 1737-1744.	0.5	6
33	Lack of awareness of liver organ damage in patients with type 2 diabetes. Acta Diabetologica, 2021, 58, 651-655.	2.5	6
34	Peripheral artery disease and all-cause and cardiovascular mortality in patients with NAFLD. Journal of Endocrinological Investigation, 2022, 45, 1547-1553.	3.3	6
35	Hypercortisolism and altered glucose homeostasis in obese patients in the preâ€bariatric surgery assessment. Diabetes/Metabolism Research and Reviews, 2021, 37, e3389.	4.0	5
36	Advances in fibrosis biomarkers in nonalcoholic fatty liver disease. Advances in Clinical Chemistry, 2022, 106, 33-65.	3.7	5

3

STEFANO CIARDULLO

#	Article	IF	CITATIONS
37	Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States. Obesity Surgery, 2022, 32, 712-719.	2.1	4
38	P Resting Whole Body Energy Metabolism in Class 3 Obesity; from Preserved Insulin Sensitivity to Overt Type 2 Diabetes (P). Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 489-497.	2.4	3
39	Hepatitis C virus infection and diabetes: a complex bidirectional relationship. Diabetes Research and Clinical Practice, 2022, , 109870.	2.8	3
40	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 3061-3062.	4.4	1
41	Metabolic and Psychological Features are Associated with Weight Loss 12 Months After Sleeve Gastrectomy. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3087-e3097.	3.6	1
42	An unexpected bilateral mass after total thyroidectomy. Endocrine, 2021, 73, 758-761.	2.3	O
43	Reply to "Liver fibrosis assessed by transient elastography and albuminuria― Digestive and Liver Disease, 2021, 53, 1056.	0.9	0
44	Comment on "An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD― Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
45	Authors' reply to Shang et al International Journal of Cardiology, 2022, , .	1.7	O